Clinical Trial Update: 6-Month Safety And Efficacy Study Of TTP488 In Patients With Type 2 Diabetes And Persistent Albuminuria [Phase 2]

View source ↗

Summary

Pfizer completed a 6-month Phase 2 study assessing the safety and efficacy of TTP488 in patients with type 2 diabetes and persistent albuminuria (diabetic nephr…

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Diabetic Nephropathy

Drugs mentioned

• TTP488

Snippet

Sponsor: Pfizer | Conditions: Diabetic Nephropathy | Phase 2 | Status: COMPLETED